Respiratory syncytial virus: desperately seeking solutions
Prescriber
; 34(4):23-26, 2023.
Artigo
em Inglês
| EMBASE | ID: covidwho-20236237
ABSTRACT
Respiratory syncytial virus (RSV) infection remains a major public health problem, especially in younger children and the elderly. But several monoclonal antibodies, antivirals and vaccines, either recently launched or in development, offer new hope for RSV prevention and treatment.Copyright © 2023 Wiley Interface Ltd.
antiviral therapy; article; asthma; bronchiolitis; common cold; coronavirus disease 2019; coughing; fever; hand washing; health service; hospital admission; hospitalization; hospitalization cost; human; Human respiratory syncytial virus; immunization; influenza; intensive care; loss of appetite; lower respiratory tract infection; lung dysplasia; malaise; meta analysis (topic); nonhuman; pneumococcal infection; pneumococcal pneumonia; pneumonia; respiratory syncytial virus infection/dt [Drug Therapy]; rhinorrhea; social distancing; sore throat; nirsevimab/dt [Drug Therapy]; palivizumab/dt [Drug Therapy]; respiratory syncytial virus vaccine/dt [Drug Therapy]; ribavirin/dt [Drug Therapy]
Texto completo:
Disponível
Coleções:
Bases de dados de organismos internacionais
Base de dados:
EMBASE
Tópicos:
Vacinas
Idioma:
Inglês
Revista:
Prescriber
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS